2.05
+0.09(+4.59%)
Currency In USD
| Previous Close | 1.96 |
| Open | 2 |
| Day High | 2.08 |
| Day Low | 1.86 |
| 52-Week High | 30.43 |
| 52-Week Low | 1.1 |
| Volume | 193,392 |
| Average Volume | 244,616 |
| Market Cap | 5.12M |
| PE | 0.05 |
| EPS | 40.06 |
| Moving Average 50 Days | 1.53 |
| Moving Average 200 Days | 7.07 |
| Change | 0.09 |
If you invested $1000 in GRI Bio, Inc. (GRI) since IPO date, it would be worth $0.01 as of July 30, 2025 at a share price of $1.89. Whereas If you bought $1000 worth of GRI Bio, Inc. (GRI) shares 2 years ago, it would be worth $0.11 as of July 30, 2025 at a share price of $1.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
GlobeNewswire Inc.
Jul 22, 2025 12:45 PM GMT
– Video webcast now available on-demand LA JOLLA, CA, July 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators f
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire Inc.
Jul 01, 2025 12:45 PM GMT
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 2- and 6-week interim safety results demonstrated GRI-0621 to be safe and well
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire Inc.
Jun 26, 2025 12:00 PM GMT
The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the fi